Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry

被引:37
作者
Edwards, SR [1 ]
Smith, MT [1 ]
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 814卷 / 02期
关键词
morphine; morphine-3-glucuronide; oxycodone; noroxycodone; high performance liquid chromatography; electrospray ionization; tandem mass spectrometry;
D O I
10.1016/j.jchromb.2004.10.035
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An assay using high performance liquid chromatography (HPLC)-electrospray ionization-tandem mass spectrometry (ESI-MS-MS) was developed for simultaneously determining concentrations of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone, in 50 mul samples of rat serum. Deuterated (d(3)) analogues of each compound were used as internal standards. Samples were treated with acetonitrile to precipitate plasma proteins: acetonitrile was removed from the supernatant by centrifugal evaporation before analysis. Limits of quantitation (ng/ml) and their between-day accuracy and precision (%deviation and %CV) were-morphine, 3.8 (4.3% and 7.6%); morphine-3-glucuronide, 5.0 (4.5% and 2.9%); oxycodone, 4.5 (0.4% and 9.3%); noroxycodone, 5.0 (8.5% and 4.6%). (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 27 条
[1]   Routine determination of morphine, morphine 3-β-D-glucuronide and morphine 6-β-D-glucuronide in human serum by liquid chromatography coupled to electrospray mass spectrometry [J].
Blanchet, M ;
Bru, G ;
Guerret, M ;
Bromet-Petit, M ;
Bromet, N .
JOURNAL OF CHROMATOGRAPHY A, 1999, 854 (1-2) :93-108
[2]   Peak fronting in reversed-phase high-performance liquid chromatography:: a study of the chromatographic behavior of oxycodone hydrochloride [J].
Broglé, K ;
Ornaf, RM ;
Wu, D ;
Palermo, PJ .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 19 (05) :669-678
[3]   Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain [J].
Bruera, E ;
Belzile, M ;
Pituskin, E ;
Fainsinger, R ;
Darke, A ;
Harsanyi, Z ;
Babul, N ;
Ford, I .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3222-3229
[4]   A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma [J].
Dawson, M ;
Fryirs, B ;
Kelly, T ;
Keegan, J ;
Mather, LE .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2002, 40 (01) :40-44
[5]   Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone [J].
Heiskanen, T ;
Olkkola, KT ;
Kalso, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) :603-611
[6]   Controlled-release oxycodone and morphine in cancer related pain [J].
Heiskanen, T ;
Kalso, E .
PAIN, 1997, 73 (01) :37-45
[7]  
HUANG L, 2003, P AUST SOC CLIN EXP, V10, P268
[8]   Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone [J].
Kaiko, RF ;
Benziger, DP ;
Fitzmartin, RD ;
Burke, BE ;
Reder, RF ;
Goldenheim, PD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :52-61
[9]   INTRAVENOUS MORPHINE AND OXYCODONE FOR PAIN AFTER ABDOMINAL-SURGERY [J].
KALSO, E ;
POYHIA, R ;
ONNELA, P ;
LINKO, K ;
TIGERSTEDT, I ;
TAMMISTO, T .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1991, 35 (07) :642-646
[10]   Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes [J].
Lalovic, B ;
Phillips, B ;
Risler, LL ;
Howald, W ;
Shen, DD .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (04) :447-454